Peptides
Beyond Ozempic: Survodutide's Dual-Receptor Bet and the Next Wave of Incretin Drugs
A phase 3 trial of a glucagon/GLP-1 dual agonist lands alongside a semaglutide biosimilar and new cardiometabolic signals — incretin therapy is outgrowing the obesity box.